Literature DB >> 16179595

Inhibition of the renin-angiotensin system prevents free fatty acid-induced acute endothelial dysfunction in humans.

Saiko Watanabe1, Tatsuya Tagawa, Ken Yamakawa, Michio Shimabukuro, Shinichiro Ueda.   

Abstract

OBJECTIVE: An elevated free fatty acid (FFA) level impairs endothelium-dependent vasodilation in humans, which may be pathophysiologically relevant to the development of endothelial dysfunction in patients with insulin resistance. We investigated the effect of inhibition of the renin-angiotensin system (RAS) on FFA-induced endothelial dysfunction. METHODS AND
RESULTS: Changes in forearm blood flow during intra-arterial infusion of acetylcholine were measured by plethysmography before and after systemic infusion of lipid/heparin in 10 healthy subjects given a single dose of placebo, losartan (50 mg), or perindopril (8 mg). Endothelial function after lipid/heparin infusion was also investigated with the coinfusion of vitamin C or NG-monomethyl-L-arginine (L-NMMA). Elevated FFA significantly reduced the response to acetylcholine by 37.7% (P=0.0096) without L-NMMA, but not the response with L-NMMA, whereas FFA did not affect the response to nitroprusside. The single dose of either losartan or perindopril completely prevented FFA-induced endothelial dysfunction. Vitamin C also prevented FFA-induced endothelial dysfunction.
CONCLUSIONS: Elevated FFA levels by lipid/heparin infusion, which may partly mimic the abnormal lipid profile in patients with insulin resistance, caused endothelial dysfunction via RAS activation and the presumably resultant oxidative stress in humans. Our results suggest the therapeutic rationale for RAS inhibition in patients with high FFA levels.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16179595     DOI: 10.1161/01.ATV.0000187465.55507.85

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  23 in total

Review 1.  Pharmacological treatment and therapeutic perspectives of metabolic syndrome.

Authors:  Soo Lim; Robert H Eckel
Journal:  Rev Endocr Metab Disord       Date:  2014-12       Impact factor: 6.514

Review 2.  The link between metabolic abnormalities and endothelial dysfunction in type 2 diabetes: an update.

Authors:  Hanrui Zhang; Kevin C Dellsperger; Cuihua Zhang
Journal:  Basic Res Cardiol       Date:  2011-12-22       Impact factor: 17.165

Review 3.  Microvascular dysfunction: an emerging pathway in the pathogenesis of obesity-related insulin resistance.

Authors:  Dennis M J Muris; Alfons J H M Houben; Miranda T Schram; Coen D A Stehouwer
Journal:  Rev Endocr Metab Disord       Date:  2013-03       Impact factor: 6.514

4.  Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome.

Authors:  Melvin R Hayden; James R Sowers
Journal:  J Am Soc Hypertens       Date:  2008-06-02

Review 5.  Human obesity and endothelium-dependent responsiveness.

Authors:  Umberto Campia; Manfredi Tesauro; Carmine Cardillo
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

6.  The combination of homozygous MTHFR 677T and angiotensin II type-1 receptor 1166C variants confers the risk of small-vessel-associated ischemic stroke.

Authors:  Zoltan Szolnoki; Anita Maasz; Lili Magyari; Katalin Horvatovich; Bernadett Farago; Ferenc Somogyvari; Andras Kondacs; Mihaly Szabo; Anita Bodor; Ferenc Hadarits; Bela Melegh
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

Review 7.  Effect of Angiotensin-converting enzyme inhibitors and Angiotensin receptor antagonists in atherosclerosis prevention.

Authors:  Maria M Patarroyo Aponte; Gary S Francis
Journal:  Curr Cardiol Rep       Date:  2012-08       Impact factor: 2.931

8.  Activities of asymmetric dimethylarginine-related enzymes in white adipose tissue are associated with circulating lipid biomarkers.

Authors:  Hiroaki Iwasaki
Journal:  Diabetol Metab Syndr       Date:  2012-04-30       Impact factor: 3.320

Review 9.  A review of Perindopril in the reduction of cardiovascular events.

Authors:  Duncan J Campbell
Journal:  Vasc Health Risk Manag       Date:  2006

Review 10.  Evolving treatment options for prevention of cardiovascular events in high-risk hypertensive patients.

Authors:  Prakash Deedwania
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-11       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.